EUVIMEDEUVIMED entdecken
StudienprotokollOpen Access · CC BY-NC-ND 3.0

Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome

Muhammad Tariq Shakoor, Samia Ayub, Sajid Dhakam

IJC Heart & Vessels · 2014

DOI: 10.1016/j.ijchv.2014.03.007 ↗

Kurz gefasst

Studienprotokoll in der Zeitschrift IJC Heart & Vessels, 2014. Verfasst von Muhammad Tariq Shakoor und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mount Auburn Hospital, Cambridge, MA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Abciximab reduces major adverse cardiac events in patients with ST elevation myocardial infarction undergoing primary percutaneous coronary intervention (pPCI). Standard protocol is intravenous abciximab bolus during PCI plus abciximab infusion for 12-18 h post pPCI. Intracoronary (IC) abciximab bolus administration results in high local drug concentrations and hence it should have higher antiplatelet effect. In this study, we assess the short-term efficacy and safety of IC compared to IV bolus of abciximab in ACS patients during pPCI. METHODS: We compared the clinical outcomes between the IC (n = 56) and standard protocol (n = 170) group of patients. Primary endpoints included bleeding/vascular/ischemic complications and MACE. RESULTS: The two groups were similar with respect to baseline characteristics. IC abciximab bolus only reduced bleeding complications, with no moderate bleed versus 7.2% in standard protocol group (p value 0.04). Ischemic/vascular complications had statistically insignificant difference between the two groups. CONCLUSION: We found no significant difference between IC abciximab bolus only and standard abciximab therapy in terms of ischemic/vascular complications and MACE. But there was higher risk of moderate bleed in standard therapy group. The IC bolus route of abciximab may be superior to the intravenous route. Prospective randomized trials are warranted to validate these findings.

Schlagwörter

Stichwörter der Autor:innen

AbciximabAcute coronary syndromePrimary percutaneous coronary intervention

Autor:innen und Institutionen

  • Mount Auburn Hospital, Cambridge, MA.
  • Aga Khan University, Karachi, Pakistan.

Zitieren

APA

Shakoor, M. T., Ayub, S., & Dhakam, S. (2014). Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome. IJC Heart & Vessels. https://doi.org/10.1016/j.ijchv.2014.03.007

Vancouver

Shakoor MT, Ayub S, Dhakam S. Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome. IJC Heart & Vessels. 2014. doi:10.1016/j.ijchv.2014.03.007

BibTeX
@article{Shakoor2014,
  author = {Shakoor, Muhammad Tariq and Ayub, Samia and Dhakam, Sajid},
  title = {Complications of intracoronary abciximab bolus-only versus standard protocol during percutaneous coronary intervention in acute coronary syndrome},
  journal = {IJC Heart & Vessels},
  year = {2014},
  doi = {10.1016/j.ijchv.2014.03.007}
}
Kostenlos starten →